Current clinic-based and peptide-research guides consistently report this 22.5 mg twice-weekly pattern as the most common experimental protocol
Meanwhile, GIP activation improves blood sugar processing and insulin regulation
The starting dose is 1 mg subcutaneously once weekly, regardless of body weight, prior experience, or goals
The company declined to do an interview with Spotlight on America, but provided this statement: Patient safety is a top priority for Novo Nordisk, and we take all reports about adverse events from the use of our medicines very seriously
Seek urgent medical attention or attend A&E if you experience severe persistent abdominal pain (especially radiating to the back), persistent vomiting preventing fluid intake, difficulty breathing, facial swelling, or yellowing of skin or eyes